Alterity Faces ASX Scrutiny Over Timing of Market-Sensitive MRI Study Announcement
Author: Benzinga Newsdesk | August 04, 2025 06:59am
Alterity Therapeutics Limited (‘ATH'): ASX Aware Letter
ASX refers to the following:
A.
ATH's announcement titled ‘Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study' (the ‘Announcement') released on the ASX Market Announcements Platform (‘MAP') at 10:08 AM on 24 July 2025 disclosing that a neuroimaging measure developed in ATH's Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study was featured in the peer- reviewed journal Annals of Clinical and Translational Neurology (the ‘Information'). The publication being entitled ‘The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy' (the ‘Article'). The Announcement was indicated to be market-sensitive by ATH when it was submitted to MAP.
B.
The Wiley Online Library Website, which discloses that the Article was first published on 14 July 20251.
C.
ASX's letter dated 11 July 2025 (‘Price Query Letter') and ATH's letter in response dated 14 July 2025 (‘Price Query Response'). Both the Price Query Letter and Price Query Response were released together on MAP on 14 July 2025. In the Price Query Response in response to question 1, ATH stated it was not aware of any information concerning it that had not been announced to the market which, if known, could explain recent trading in its securities. ASX notes that ATH's answer to question 3 in the Price Query Response does not make mention of the Article.
D.
The change in the price of ATH's securities from a low of $0.013 immediately prior to the release of the Announcement to a high of $0.015 at close of trade on 24 July 2025 following the release of the Announcement.
E.
Listing Rule 3.1, which requires a listed entity to immediately give ASX any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities.
F.
The definition of "aware" in Chapter 19 of the Listing Rules, which states that:
"an entity becomes aware of information if, and as soon as, an officer of the entity (or, in the case of a trust, an officer of the responsible entity) has, or ought reasonably to have, come into possession of the information in the course of the performance of their duties as an officer of that entity."
G.
Section 4.4 in Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B titled "When does an entity become aware of information?"
H.
Listing Rule 3.1A, which sets out exceptions from the requirement to make immediate disclosure as follows.
